Picture of PolyPeptide AG logo

PPGN PolyPeptide AG Cashflow Statement

0.000.00%
ch flag iconLast trade - 00:00
HealthcareSpeculativeMid CapSucker Stock

Annual cashflow statement for PolyPeptide AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

C2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line31.347.37.77-51.4-19.6
Depreciation
Non-Cash Items13.722.76.8316.713.7
Other Non-Cash Items
Changes in Working Capital-13.1-33.3-35.240.762.5
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities49.557.45.4636.589.4
Capital Expenditures-43.2-77.7-78.8-56.7-87
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items0.641-3.140.329-2.78-4.05
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-42.6-80.8-78.4-59.5-91
Financing Cash Flow Items0-4.380
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-6.73131-26.984.5-25.3
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-0.3119-98.858.2-27.4